The global nanopharmaceutical drugs market is projected to be worth USD 82.71 Billion by 2027, according to a current analysis by Emergen Research. The nanopharmaceutical drugs market is observing high demand attributed to the rising incidence of cancer. Cancer significantly impacts the societal and economic growth in the US and worldwide and is a major contributor to the cost burden of disease. It has been anticipated that 1,806,590 new cancer cases are likely to be diagnosed in the US in 2020, and 606,520 deaths will occur owing to the disease. The advantages offered by nanopharmaceutical drugs comprise targeting lesions/tumor cells, apoptosis commencement, and drug accumulation in specific tissue for improved cancer cells’ exposure cells. Existing pharmaceuticals formulation into the nanoscale has resulted in lower toxicity levels and better cell specificity.
Based on the in-depth analysis the research also brings to light major facts pertaining to the vital aspects such as market share, size, and growth rate. Deep dive into other aspects including the investment feasibility, demand and supply, import and export status, supply chain management and growth prospects narrates a lot about what the business environment will be like for the forecast period,2020 - 2027. All the vital statistics in the report are explained with the help of resources such as tables, charts, and info graphics.
The nanopharmaceutical drugs have been garnering significant market traction due to the ability of such drug systems to overcome restrictions and issues associated with conventional pharmaceutical agents, preparations, and delivery systems. A major concern linked with conventional drug delivery systems is the removal of residual parts of such systems, consequently leaving non-biodegradable substances, which may lead to toxicity issues, in the body of a patient. Also, most of the conventional drug delivery systems have a high initial drug release burst instantly after drug administration, along with low drug solubility.
Read more@ https://www.emergenresearch.com/industry-report/nanopharmaceutical-drugs-market
Key Highlights From The Report
In February 2019, Sanofi entered into a definitive agreement with NH TherAGuIX for the introduction of AGuIX® Nanoparticle in the field of cancer treatment. This agreement offers NH TherAGuIX the benefit to gain from the experience and industrial expertise of Sanofi in producing active pharmaceutical ingredients (API).
Microemulsion formulations are considered to be advantageous compared to conventional oral formulations and provide improved absorption, increased clinical potency, and decreased drug toxicity.
The application of nanotechnologies has extremely transformed the pharmaceutical and biotechnology sector landscape, with nearly 100 nanomedicine products at present being sanctioned for clinical use varying from drug delivery to and medical devices.
Nanopharmaceutical drugs for antimicrobial drug delivery provide unique benefits in reducing resistance and triggering fewer side effects compared to conventional antibiotics. Nanopharmaceutical drugs can induce efficient immune responses compared to microbial infection.
The market in the North American region held the largest market share in 2019, owing to high adoption of advanced diagnostic procedures, a rising incidence of chronic conditions, established healthcare infrastructure, and undertaking of various initiatives to create awareness about the disease.
Key participants include Amgen Inc., AstraZeneca PLC, Gilead Sciences Inc., Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Johnson & Johnson, Pfizer Inc., Sanofi SA, and Merck & Co. Inc., among others.
Request For Free Sample@ https://www.emergenresearch.com/request-sample/378
Type Outlook (Revenue, USD Billion; 2017-2027)
Liposomes
Polymeric Micelles
Microemulsion
Solid Lipid Nanoparticles
Nanoemulsion
Others
Application Outlook (Revenue, USD Billion; 2017-2027)
Oncology
Cardiovascular/Physiology
Anti-inflammatory/Immunology
Neurology
Anti-Infective
Others
Distribution Channel Outlook (Revenue, USD Billion; 2017-2027)
Hospital Pharmacies
Retail Off-Line Pharmacies
Retail On-Line Pharmacies
Regional Outlook (Revenue, USD Billion; 2017-2027)
North America
Europe
Asia Pacific
Latin America
MEA
Table of Content
Chapter 1. Methodology & Sources
1.1. Nanopharmaceutical Drugs Market Definition
1.2. Nanopharmaceutical Drugs Research Scope
1.3. Nanopharmaceutical Drugs Market Methodology
1.4. Nanopharmaceutical Drugs Market Research Sources
1.4.1. Primary
1.4.2. Secondary
1.4.3. Paid Sources
1.5. Nanopharmaceutical Drugs Market Estimation Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2019-2027
Chapter 3. Key Insights
Chapter 4. Nanopharmaceutical Drugs Market Segmentation & Impact Analysis
Continued…
